These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34636627)

  • 1. Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.
    Sartor O; George D; Tombal B; Agarwal N; Higano CS; Sternberg CN; Miller K; Jiao X; Guo H; Sandström P; Bruno A; Verholen F; Saad F; Shore N
    Future Oncol; 2022 Jan; 18(1):35-45. PubMed ID: 34636627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
    Shore N; Higano CS; George DJ; Sternberg CN; Saad F; Tombal B; Miller K; Kalinovsky J; Jiao X; Tangirala K; Sartor O
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):680-688. PubMed ID: 32404868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    Kim SI; Szeto AH; Morgan KP; Brower B; Dunn MW; Khandani AH; Godley PA; Rose TL; Basch EM; Milowsky MI; Whang YE; Crona DJ
    PLoS One; 2021; 16(6):e0253021. PubMed ID: 34153052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without
    Caffo O; Frantellizzi V; Monari F; Galli L; Costa RP; Pinto C; Tucci M; Baldari S; Facchini G; Bortolus R; Alongi F; Alongi P; Donner D; Fanti S; Sbrana A; Morabito A; Masini C; Zichi C; Pignata S; Borsatti E; Salgarello M; Spada M; De Giorgi U; Lo Re G; Cortesi E; De Vincentis G
    Cancer Biother Radiopharm; 2021 Jun; 36(5):391-396. PubMed ID: 33769088
    [No Abstract]   [Full Text] [Related]  

  • 5. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
    Petrylak DP; Vaishampayan UN; Patel KR; Higano CS; Albany C; Dawson NA; Mehlhaff BA; Quinn DI; Nordquist LT; Wagner VJ; Siegel J; Trandafir L; Sartor O
    ESMO Open; 2021 Apr; 6(2):100082. PubMed ID: 33744812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
    Thiery-Vuillemin A; Poulsen MH; Lagneau E; Ploussard G; Birtle A; Dourthe LM; Beal-Ardisson D; Pintus E; Trepiakas R; Lefresne F; Lukac M; Van Sanden S; Pissart G; Reid A;
    Eur Urol; 2020 Mar; 77(3):380-387. PubMed ID: 31594705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States.
    George DJ; Sartor O; Miller K; Saad F; Tombal B; Kalinovský J; Jiao X; Tangirala K; Sternberg CN; Higano CS
    Clin Genitourin Cancer; 2020 Aug; 18(4):284-294. PubMed ID: 32057714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
    Zhao H; Howard LE; De Hoedt AM; Terris MK; Amling CL; Kane CJ; Cooperberg MR; Aronson WJ; Klaassen Z; Polascik TJ; Vidal AC; Freedland SJ
    Prostate; 2021 May; 81(7):390-397. PubMed ID: 33705584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower Fracture Rates in Patients Treated with Radium-223, Abiraterone or Enzalutamide, When Given Concurrently with Bone Health Agents: A Real-World Analysis.
    Trieu J; Chang M; Rojas V; Varada N; Cao Y; Anderson M; Vogelzang NJ
    Clin Genitourin Cancer; 2022 Oct; 20(5):399-403. PubMed ID: 35680530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C
    Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
    Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
    Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
    de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
    Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases.
    McGregor B; Zhang L; Gray KP; Shaw G; Evan C; Francini E; Sweeney C
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):341-348. PubMed ID: 32884090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.
    Westgeest HM; Kuppen MCP; van den Eertwegh AJM; de Wit R; Bergman AM; van Moorselaar RJA; Coenen JLLM; van den Bergh ACM; Somford DM; Mehra N; van Oort IM; Aben KKH; Gerritsen WR; Uyl-de Groot CA
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):871-879. PubMed ID: 33746212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study.
    Matsubara N; Kimura G; Uemura H; Uemura H; Nakamura M; Nagamori S; Mizokami A; Kikukawa H; Hosono M; Kinuya S; Krissel H; Siegel J; Kakehi Y
    Int J Clin Oncol; 2020 Apr; 25(4):720-731. PubMed ID: 31823152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Combination Therapy With Radium-223 and Enzalutamide in Castration-resistant Prostate Cancer With Bone Metastases.
    Wakita N; Hara T; Suzuki K; Terakawa T; Teishima J; Nakano Y; Miyake H
    Anticancer Res; 2024 Jun; 44(6):2627-2635. PubMed ID: 38821616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical case of a patient undergoing radium-223 treatment following treatment with abiraterone acetate and enzalutamide.
    Jiménez Romero ME; Díez Farto S; Navarro Serrato JS; Canelón Castillo E; Revelo Cadena I
    Exp Oncol; 2018 Jun; 40(2):144-148. PubMed ID: 29949528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radium-223 (Xofigo) with concurrent abiraterone or enzalutamide: predictive biomarkers of improved overall survival in a clinically advanced cohort.
    Rathbun JT; Franklin GE
    Curr Probl Cancer; 2019 Jun; 43(3):205-212. PubMed ID: 29983206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study.
    Barata PC; Leith A; Ribbands A; Montgomery R; Last M; Arondekar B; Ivanova J; Niyazov A
    Oncologist; 2023 Sep; 28(9):e737-e747. PubMed ID: 37014097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
    Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
    Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.